$Novavax(NVAX)$ bearish Investors have been rapidly selling popular meme Pharma play Novavax (NASDAQ: NVAX), due to delays in its Covid-19 vaccine launch. The company’s financial concerns were evident as it reported a Q4 2022 net loss of $182 million. Management’s uncertainty about 2023 revenue, linked to U.S. government funding, has also been expressed. Nonetheless, cost reduction efforts and positive vaccine trial results have led to a projected revenue range of $1.4 billion to $1.6 billion for the year.
Despite generating substantial sales from its vaccine candidate Nuvaxovid, the company faced large operating losses in 2021 and 2022, a trend that persists according to recent quarterly results. Despite a significant drop in stock price and a settlement from the Canadian government, caution is advised due to ongoing operational challenges.
Comments
I would short the puts, buy the shares. Today is just the beginning, strategic long term investors won't even sell for those pennies. Holding for 100.
Gotta love shorts that are trying hard here to act like 10.6M doses sold to Germany is nothing. Incredible.
$20B market cap. Nothing less. Pay up.
NVAX will never allow this to happen - who do you think was selling today when it SP got to mid 8.s
Does anyone know what the 10.6 million doses of Novavax cost?
NVAX hopes so they have shares ready to sell - Go for it help NVAX raise money